European Union´s Horizon 2020 – Lipum2020-06-23T06:45:31+02:00


Novel Target for Treatment of Chronic Inflammatory Diseases — Notid

2611, 2019

Pharma Outsourcing 2019

november 26th, 2019|

“How we selected our CMO partner for cell line and production development of Lipum´s lead candidate drug SOL-116” […]

1510, 2019

BioStock Life Science Summit

oktober 15th, 2019|

Life Science industry leaders, financing experts and qualified investors gather in Lund. Welcome to meet us at Biostock Life Science Summit, october 23th-24th. […]

3009, 2019

Lipum participates in investment and partnering meeting

september 30th, 2019|

Today, our COO, Pernilla Abrahamsson, is traveling to Paris to participate at French-Swedish Life Science Days 2019. The goal of the conference is to establish new contacts and identify business and collaboration opportunities. The conference will gather early stage and highly innovative medtech and biotech companies from Sweden and France, [...]

1909, 2019

Lipum to Basel for one-to-one meetings

september 19th, 2019|

- We are looking forward to one-to-one meetings in Basel, among the largest biopharma hubs in Europe, says CEO Einar Pontén when Lipum is preparing to participate at the 19th Annual Biotech in Europe Forum (Sachs) on September 25-26.

2508, 2019

Lipum attends the largest Nordic Partnering Conference

augusti 25th, 2019|

- This is the right arena for Lipum, says Einar Pontén. It gives us an opportunity to meet people and inform about our progress and long-term plan. Lipum will participate September 10-12th at Nordic Life Science Days, the largest Nordic partnering conference dedicated to the life science industry. The NLSDays [...]

2408, 2019

BioStock’s article series on autoimmune disease: Drug development for RA and MS

augusti 24th, 2019|

Therapies for autoimmune diseases are available but do not work for all patients, and when they do, side effects can be severe. There is a strong need for new therapies and therefore there is a large market potential, especially for treatments targeting rheumatoid arthritis and multiple sclerosis. In this third segment [...]

European Commission Horizon 2020
SME Instrument phase 1 No 744248
SME Instrument phase 2 No 829741

Project title:
Novel Target for Treatment of Chronic Inflammatory Diseases

Project budget:
3.2 M€

Funding from the EU:
2.2 M€



Till toppen